3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 4
1
Phase 2
1
Status
Completed
5
Sponsor Class
INDUSTRY
4
OTHER
1
Study Type
Interventional
4
Observational
1
Sponsor
Cancer Type
Breast
136
Endocrine
5
Thoracic
4
Tumor-Agnostic
3
Gynecologic
3
Genitourinary
3
Other solid neoplasm
2
Lymphoid
2
Gastrointestinal
2
Sarcoma
1
Other neoplasm
1
Conditions
Multiple Endocrine Neoplasia Type 1
5
Breast Neoplasms
3
Neoplasms
2
Neoplasm Metastasis
2
Neoplasms by Site
1
Hyperglycemia
1
Breast Diseases
1
Interventions
Everolimus
32
Octreotide
15
Cisplatin
14
pasireotide
13
Sunitinib
13
Temozolomide
11
pembrolizumab
10
Etoposide
10
Doxorubicin
10
lanreotide
9
Magnetic Resonance Spectroscopy
9
Bevacizumab
9
lutetium Lu 177 dotatate
8
gallium Ga 68 dotatate
8
Sorafenib
8
Paclitaxel
8
3-Iodobenzylguanidine
8
lenvatinib
7
pazopanib
6
Radiotherapy
6
Positron Emission Tomography Computed Tomography
6
Nivolumab
6
surufatinib
5
cabozantinib
5
avelumab
5
Thyrotropin Alfa
5
Surgical Procedures, Operative
5
Radiosurgery
5
Mitotane
5
Irinotecan
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
5 trials
Recent
Start date
Enrollment
Completed
×
Fulvestrant
×
Endocrine
×
Clear all
NCT05631795
2026-04-07
ALPINIST
Novartis
Phase 4
Completed
40 enrolled
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled
NCT02437318
2025-02-13
SOLAR-1
Novartis
Phase 3
Completed
572 enrolled
22 charts
1 FDA
NCT02422615
2023-11-30
MONALEESA-3
Novartis
Phase 3
Completed
726 enrolled
17 charts
1 FDA
NCT02753686
2023-02-15
Treat ER+ight
Novartis
Completed
440 enrolled